| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 149.58 | 3.3% | 4.6% |
| Total Income | 149.58 | 3.3% | 4.6% |
| Expenditure | 124.04 | 5.1% | 1.6% |
| PBT | 38.23 | 45.7% | 93.9% |
| Net Profit | 17.76 | 7.3% | 29.7% |
| OPM | 17.07% | 1.44pp | 2.43pp |
| NPM | 11.87% | 1.37pp | 2.30pp |
| EPS | 0.62 | 7.5% | 31.9% |
CTS Corporation Reports Q3 2026 Results, Raises 2026 Outlook
27 Oct 2026 · 27 Oct, 5:31 pm
Summary
CTS Corporation reported a strong third quarter of 2026 with sales reaching $149.6 million, a 5% increase year-over-year, driven by continued strength in its diversified portfolio. Net income rose to $17.8 million, and diluted EPS increased to $0.61. The company achieved record profitability with Adjusted Gross margin at 42.2% and Adjusted EBITDA margin at 24.7%. Management raised the full-year 2026 outlook for both sales and adjusted diluted EPS, citing disciplined execution and the advancement of its diversification strategy through acquisitions like Millar.
Key Highlights
- 1
CTS Corporation announced third quarter 2026 sales of $149.6 million, an increase of 5% year-over-year.
- 2
Net income for the third quarter of 2026 was $17.8 million, an improvement from $13.7 million in the prior year's quarter.
- 3
Diluted Earnings Per Share (EPS) reached $0.61, up from $0.46 in the third quarter of 2025.
- 4
Adjusted Gross margin improved significantly to 42.2%, a 330 basis point increase compared to the third quarter of 2025.
- 5
Adjusted EBITDA margin was 24.7%, up 90 basis points from 23.8% in the third quarter of 2025.
- 6
Operating cash flow for the quarter was $43.5 million, an increase of $14.5 million compared to the third quarter of 2025.
- 7
The company raised its 2026 guidance for sales to a range of $580-$590 million and adjusted diluted EPS to $2.78-$2.88.
Management Comments
Pratik Trivedi
CTS delivered another strong quarter, with sales increasing 5% year over year, driven by continued strength across our increasingly diversified portfolio. Diversified end-market sales grew 7% and now represent 60% of total sales, while Transportation sales also posted modest growth. Our disciplined execution is delivering profitable growth, record margins and strong cash generation. The acquisition of Millar further advances our diversification strategy, especially in the medical end market, and enhances our opportunity to create sustainable long-term value.
Informational and educational content only. Not investment advice.